Treatment with recombinant human erythropoietin in children with malignancies

Pediatric Hematology and Oncology

Volumn 13, Issue 2, 1996, Pages 111-121

  Bolonaki, I ^a,b   Stiakaki, E ^a   Lydaki, E ^a   Dimitriou, H ^a   Kambourakis, A ^a   Kalmantis, Th ^a   Kalmanti, M ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

anemia; children; leukemias; lymphomas; malignant diseases; recombinant erythropoietin; solid tumors

Indexed keywords

FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; ERYTHROCYTE CONCENTRATE; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HUMAN; INFANT; LEUKEMIA; LEUKOCYTE COUNT; LYMPHOMA; MALE; QUALITY OF LIFE; SOLID TUMOR; THROMBOCYTE COUNT;

EID: 0029939967     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019609030801     Document Type: Article

References (32)

1. Johnson R, Roodman G. Haematologic manifestations of malignancy. Dis Mon. 1989;35:726-768.
2. Cartwright GE. The anemia of chronic disorders. Semin Hematol. 1966;3:351.
3. Miller CB, Jones RJ, Piantadosi S, Adeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322:1689-1692.
4. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977; 252:5558-5564.
5. Watkins PC, Eddy R, Hoffman N, et al. Regional assignment of the erythropoietin gene to human chromosome region 7pter-q22. Cytogenet Cell Genet. 1986;42:214-218.
6. Miller CB, Platanias LC, Mills SR, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst. 1992;84:98-102.
7. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin. Treatment in chronic anemia of cancer. Blood. 1994;84:1056-1063.
8. Spivak J. Recombinant human erythropoietin and the anemia of cancer. Blood. 1994;84:997-1004.
9. Dainiak N, Kulkarni V, Howard D, Kalmanti M, Dewey MC, Hoffman R. Mechanisms of abnormal erythropoiesis in malignancy. Cancer. 1984;51:1101-1106.
10. Boyd HK, Lappin TRJ. Erythropoietin deficiency in the anemia of chronic disorders. Eur J Haematol. 1991;46:198-201.
11. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA. 1985;82:7580-7584.
12. Eschbach JW, Egrie JC, Dowing MR, Browne JK, Adamson JW. Correction of anemia of end-stage renal disease with recombinant human erythropoietin. Results of a phase I and II clinical trial. N Engl J Med. 1987;316:73-78.
13. Cascinu S, Fedeli A, Del Ferro E, Fedel SJ, Gatalano G. Recombinant human erythropoietin treatment in cisplatin associated anemia: A randomized double-blind trial with placebo. J Clin Oncol. 1994;12:1058-1062.
14. Rudnick S, Abels R, Danna R, Milak D, Ortho Pharmaceutical Corporation Collaborative Research Group. Correction of chronic anemia in cancer patients by rHuEPO. Proc Am Soc Clin Oncol. 1990;9:182 (abstract 704).
15. Oster W, Herrmann F, Gann H, et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol. 1990;8:956-962.
16. Taylor J, MacTier RA, Stewart WK, Henderson IS. Effect of erythropoietin on anemia in patients with myeloma receiving haemodialysis. Br Med J. 1990;301:476-477.
17. Dessypris EN, Graber SE, Krantz SB, Stone WJ. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood. 1988;72:2060-2062.
18. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990;248:378-381.
19. Ludwig H, Fritz E, Leitgeb, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol. 1993;4:161-164.
20. Tracher N, on behalf of the Eprex Anaemia Prevention Study Group. Controlled study of the efficacy and safety of rHu erythropoietin in the prevention of anemia in patients with small cell lung cancer receiving chemotherapy. 25th Congress ISH, Cancun, Mexico, April 16-22, 1994. Rev Invest Clin. 1994;April suppl:Abstract 15.
21. Krantz SB. Erythropoietin. Blood. 1991;77:419-434.
22. Peter HD. Anemia in Cancer and Chemotherapy. Treatment and Care with Epoietin Alpha. Cilag Monograph Center of Pharmacology, Immunopharmacology Department, Hannover Medical School, Germany 1995:25.
23. Barlogie B, Beck T. Recombinant human erythropoietin and the anemia of myeloma. Stem Cells. 1993;11:88-94.
24. Kalmanti M, Kalmantis T. Committed erythroid progenitors and erythropoietin levels in anemic children with lymphomas and tumors. Pediatr Hematol Oncol. 1989;6:85-93.
25. Ayash L, Elias A, Hunt M, et al. Recombinant human erythropoietin for treatment of the anemia associated with autologous bone marrow transplantation. Br J Hematol. 1994;87:153-161.
26. Riehm H, Gadner H, Henze G, Kornhuber B, Nielthammer D, Schellong G. The five therapy trials ALL-BFM 1970-1986: A synopsis of results (abstract). Am Soc Clin Oncol. 1987.
27. Steinherz PG, Redner A, Steinherz L, Meyer P, Tan C, Glenn H. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan Kettering New York II protocol. Cancer. 1993;72:10-13.
28. 2 protocol with high dose methotrexate in 84 children with non-B cell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992;20:105-113.
29. Rozenthal J, Robins HI, Finlay J, et al. Eight drugs in one day chemotherapy in post-irradiated adult patients with malignant gliomas. Med Pediatr Oncol. 1989;17:471-476.
30. Pritchard J, Whelan R, Hill BT. Sequential cis-platinum and VW26 in neuroblastoma [OPEC (oncovin, platinum, etoposide, cyclophosphamide) regimen]. Laboratory and clinical studies. In: Evans AE, Angio XX, Seeger RC, eds. Advances in Neuroblastoma Research. Prog Clin Biol Res. 1984;175:545-555.
31. Grundy P, Takashima J, Evans AE. Results of salvage therapy for relapsed third National Wilm's Tumor Study (NWTS-3) patients. Proc Am Soc Clin Oncol. 1988;4:245-248.
32. Miser J, Kinseka T, Triche T, et al. Ifosphamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987;5:1191-1198.